Simulations Plus (SLP) Investor Day 2026 summary

Strategic vision, mission, and industry positioning

• Emphasizing a shift from point solutions to an integrated, cloud-enabled, AI-orchestrated ecosystem supporting the entire drug development lifecycle, including discovery, development, clinical operations, and commercialization.

• Aims to improve quality of life through innovative, science-based software and consulting solutions, guided by values of innovation, commitment, respect, wellness, and integrity.

• Industry trends such as AI adoption, cloud-native computation, and regulatory momentum for Model-Informed Drug Development (MIDD) and non-animal methodologies are accelerating, creating new opportunities.

• The acquisition of Pro-ficiency doubled the total addressable market (TAM) to $12.5 billion, with projections to reach $27.2 billion by 2030, expanding into clinical trial training and medical communications.

• The company is evolving from a tool provider to an ecosystem partner, aiming to be engaged with clients across multiple solutions and stages, supported by a client-focused, functionally integrated operating model.

Product and technology roadmap

• Transitioning to a unified, AI-orchestrated, cloud-ready ecosystem with four architectural layers: validated scientific engines, composition (Vienna), grounded intelligence (AI copilots), and orchestration.

• Focus on composability, scale, and intelligence, with validated scientific engines at the core and S+ Cloud platform enabling secure, scalable, and compliant workflows.

• Near-term (12 months): More engines exposed, cloud identity/workspaces, early cross-product workflows, and embedded AI copilots; mid-term (12–36 months): unified modeling language, mature cross-engine templates, and standard multi-product workflows; long-term (36+ months): continuous lifecycle feedback, AI across disciplines, and cloud-scale compute.

• New revenue streams include workflow-based products, premium AI copilots, cloud collaboration features, tokenized usage models, and cross-product bundles.

• Pricing evolution will focus on monetizing new layers above core engines, such as composition and AI, with cloud add-ons and optional premium AI, while maintaining stable core licensing.

Financial guidance, business model, and growth outlook

• Fiscal 2026 guidance is reaffirmed, with no change in expectations.

• R&D spending has increased and is expected to remain consistent, supporting the technology roadmap.

• Long-term sustainable growth rate for biosimulation is targeted at 14-15%, with a near-term goal to return to 10% as market conditions stabilize.

• Value compounds through deeper integration into customer workflows, increasing customer lifetime value and enterprise expansion.

• Cross-selling, solution selling, and evolving from tool sales to platform relationships are key strategies to expand account depth, recurring revenue, and margin enhancement.